anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:N-(cis-3,4-Dimethoxycinnamoyl)anthranilic acid expressed by formula I and a salt thereof. USE:An antiallergic agent useful for treating bronchial asthma, urticaria, atopic dermatitis, allergic rhinitis, etc. PROCESS:A solution of N-(trans-3,4-dimethoxycinnamoyl)anthranilic acid expressed by formula II or a salt thereof is irradiated with light containing ultraviolet rays having at least 310-315nm and/or 360-370nm, preferably 313nm and/ or 366nm, wavelength for at least 30min, preferably one hr or longer to give the aimed compound of formula I . A high pressure mercury lamp, medium pressure mercury lamp, etc. may be preferred for the irradiation light source, but direct rays of the sun, a fluorescent lamp or germicidal lamp, etc. may also be used.
A variety of topical hemostasis pads containing procoagulant materials are currently available to accelerate hemostasis after removal of the arterial introducer sheath following coronary and peripheral arterial angioplasty procedures. The effectiveness and safety of these pads, however, remains poorly understood. A total of 150 patients undergoing coronary or peripheral vascular angioplasty through a 6 French arterial sheath will be randomized to sheath removal using manual compression alone or manual compression combined with use of the SafeSeal(TM) hemostasis patch. Sheaths will be removed at an activated clotting time (ACT) of \<250 seconds, and patients will be kept at bedrest for 2 hours after hemostasis is achieved. The primary endpoint will be time to hemostasis. Secondary endpoints witll include time to ambulation and frequency of bleeding complications.
This study adopts a single-arm, multi-center, open design. As per the initial plan, 30 stage II-III human epidermal growth factor receptor 2(HER2)-positive breast cancer patients who have received neoadjuvant therapy containing trastuzumab and pertuzumab and have been assessed as stable disease (SD) during the neoadjuvant treatment (an increase of 0-20%), disease progression (PD), inoperable or failing to meet the breast-conserving requirements will be enrolled to receive pyrotinib combined with Next-generation Site-specific HER2-targeting Antibody-drug Conjugate (ARX788) neoadjuvant therapy. The main purpose of the study is to observe the efficacy and safety of pyrotinib combined with ARX788 neoadjuvant treatment in stage II-III HER2-positive breast cancer.
Disclosed are a composition for reducing skin wrinkles and improving skin elasticity, comprising an extract of Ribes Nigrum Fruit and a grape extract as effective components; a cosmetic composition for reducing skin wrinkles and improving skin elasticity using the same; and a cosmetic product for reducing skin wrinkles and improving skin elasticity using the same. The extract of Ribes Nigrum Fruit may be extracted by extracting Ribes Nigrum Fruit using at least one solution selected from the group consisting of water, an alcohol, and a mixed solution thereof, as an extraction solvent. The alcohol may include lower alcohols having 1-4 carbon atoms. The extract of Ribes Nigrum Fruit may be extracted using, as the alcohol, approximately 40-95% ethanol as the extraction solvent. The grape extract may be extracted through fermentation and drying of ground grapes. The technique disclosed in the present specification may provide the effect of reducing skin wrinkles and improving skin elasticity through the compositions comprising the extract of Ribes Nigrum Fruit and the grape extract as effective components.
Use of a paramyxovirus vector makes it possible to transfer a nucleic acid into a blood vessel at a high efficiency even by exposing to the vector with in a short period of time. Namely, a paramyxovirus vector to be used for transferring a nucleic acid into vascular cells and a nucleic acid transfer method with the use of this virus vector are provided. The gene transfer efficiency into the vascular media layer is significantly elevated by treati ng the blood vessel with a protease. The expression of the transferred gene remains stable over a long time in the vascular cells. Use of this method makes it possible to efficiently transfer a gene within a short period of ti me into the vascular cavity, media, tunica tissues, etc. in gene therapy.</SDOA B>
Methods, computer-readable media, systems, and/or apparatuses are provided for providing offer and insight generation functions. User input requesting an offer or insight may be received and an image of a photographic identification of a user may be requested. The image of the photographic identification may be captured and stored. A self-captured image of the user may be captured (e.g., via an image capture device of the computing device) and compared to an image of a user from the photographic identification. Responsive to determining that the images match, displaying an instruction to capture a vehicle identification number. The vehicle identification number may be captured. Data, including location data, may be extracted and an archive including the extracted data may be generated and the data may be transmitted to an entity computing system for processing. The entity computing system may evaluate the data and generate one or more insights and/or outputs.
Pulse oximetry is arguably the most impactful monitor ever introduced into respiratory care practice. Recently there has been increased attention to the problem of occult hypoxemia in which patients are hypoxemic despite an acceptable SpO2 Although occult hypoxemia might be greater in Black patients than white patients, it is not insignificant in whites. In a given population of patients, the bias between SpO2 and arterial oxygen saturation (SaO2 ) might be close to zero. However, the limits of agreement can be wide, meaning that SpO2 might overestimate SaO2 in many individual patients, which can result in occult hypoxemia in some. Manufactures report accuracy of SpO2 derived from normal individuals, which might differ from that in the clinical setting. That SpO2 overestimates SaO2 in an important number of individuals has caused some to recommend higher SpO2 targets to avoid occult hypoxemia. There is also evidence that suggests that SpO2 might not accurately trend SaO2 Additional research is needed to investigate strategies to mitigate the bias between SpO2 and SaO2 Clinicians must be cognizant of the limitations of pulse oximetry when clinically using SpO2 The aim of this paper is to provide an update on pulse oximetry.
BACKGROUND: Although plastic surgery procedures generally demonstrate less than 2% incidence of venous thromboembolism (VTE) outcomes, the post-COVID era data remain elusive. This study sought to elucidate the relationship between COVID-19 infection and the risk of VTE outcomes across plastic surgery procedures.
METHODS: Plastic surgery procedures were identified in the 2012-2022 National Surgical Quality Improvement Program databases. The outcomes of interest were the postoperative occurrence of VTE, defined as deep vein thrombosis (DVT) or pulmonary embolism (PE), and postoperative complication. Propensity score matching was used to 1) compare overall rates of VTE between the pre-pandemic era and pandemic era cohorts and 2) compare rates of VTE and overall postoperative complications in cases with and without COVID-19 diagnosis in the years 2021-2022 (p < 0.05).
RESULTS: Overall, 269,006 plastic surgery cases were identified, comprising general breast (76%) and trunk (9.4%) procedures. Non-breast free tissue transfer cases were associated with the highest rates of DVT (1.3%) and trunk procedures with the highest rates of PE (0.7%). After propensity score matching, the overall rate of VTE after the onset of the COVID-19 pandemic was not significantly different from the pre-pandemic era (p = 0.40). In a separately matched cohort, COVID-19 diagnosis did not significantly predict the risk for VTE (p = 0.48) but did significantly predict the risk for overall postoperative complications (p < 0.001).
CONCLUSIONS: Although COVID-19 diagnosis itself did not predict the risk of VTE in matched analysis, it significantly predicted the overall postoperative complications. Future studies may further investigate the effects of COVID-19 infection over longer periods of follow-up.
Participants will be randomized to immediate versus delayed return of pharmacogenomic results obtained from testing conducted by an independent biobanking study. Participants in the delayed group with receive a pharmacist Personalized Medication Review without PGx results. The delayed group will receive results from the independent biobanking study (Pitt+Me Discovery) at 12 months after the Personalized Medication Review.
A method of healthcare allocation includes receiving, at an artificial intelligence engine, health data from sensors over a period of time. The sensors read the health data of a plurality of patients. Thereby, as the artificial intelligence engine receives the health data, the artificial intelligence engine learns a baseline health assessment of each of the patients. After the period of time elapses, the artificial intelligence engine continuously receives the health data from the sensors. If the health data singularly or in combination indicates an absolute healthcare issue exists, the artificial intelligence engine allocates/recommends at least one resource to one of the patients that is associated with the health data. Periodically, the artificial intelligence engine scans all patients and generates a priority for help for each of the patients and then allocates/ recommends at least one resource to each patient in a subset of the patients based upon the priority.
Randomly selected participants will receive 20 min. of sham transcranial direct current stimulation to the top of their heads. Sham stimulation is accomplished by turning on the device and slowly increasing and subsequently decreasing the amount of current to zero. This occurs over 30 secs.
Each patient took the placebo (i.e., the same amount of cellulose). All patients received a mildly hypocaloric diet (i.e., -20% of the usual caloric intake as assessed by a 24-hour dietary recall).
The NLRP3 inflammasome, a multiprotein complex responsible for triggering the release of pro-inflammatory cytokines, plays a crucial role in inducing the inflammatory response associated with sepsis. While small molecule inhibitors of the NLRP3 inflammasome have been investigated for sepsis management, delivering NLRP3 inhibitors has been accompanied by several challenges, primarily related to the drug formulation, delivery route, stability, and toxicity. Many existing inflammasome inhibitors either show higher liver toxicity or require a high dosage to efficiently impede the inflammasome complex assembly. Moreover, the potential synergistic effects of combining multiple inflammasome inhibitors in sepsis therapy remain largely unexplored. Therefore, a rational approach is essential for presenting the potential administration of NLRP3 small molecule inhibitors to inhibit NLRP3 inflammasome activation effectively. In this context, we present a lipid nanoparticle-based dual-drug delivery system loaded with MCC 950 and disulfiram, demonstrating markedly higher efficiency compared to an equivalent amount of free-drug combinations and individual drug nanoparticles in vitro. This combination therapy substantially improved the in vivo survival rate of mice for LPS-induced septic peritonitis. Additionally, the synergistic approach illustrated a significant reduction in the expression of active caspase-1 as well as IL-1β inhibition integral components in the NLRP3 pathway. This study underscores the importance of integrating combination therapies facilitated by nanoparticle delivery to address the limitations of small molecule inflammasome inhibitors.
Participants are randomly allocated to receive one of two treatments, either Automatic Positive Airway Pressure (APAP) or NightBalance Sleep Position Therapy for a three month period. Participants are sent home with instructions to use that device nightly at home for three months. After three months of using the first device, they return to the doctor for assessment of the efficacy of the device using a sleep test and the compliance read from the device. Upon conclusion of the first three month treatment period, patients receive the alternative treatment for a further three months. At the end of the second three month period, participants return to their doctor again to assess the efficacy of the last device and read the compliance. Before any treatment and after each treatment, patients undergo a sleep test and complete some questionnaires. During each treatment period, patients complete a healthcare utilization diary and report any problems.
This study tests the feasibility and preliminary efficacy of a computerized cognitive training program to improve working memory and decrease impulsivity among HIV-infected individuals with poor medication adherence. The specific aims are to: (1) Investigate the effects of the cognitive training intervention on working memory and delay discounting in HIV-infected persons; and (2) Characterize adherence to antiretroviral medications in this population and examine medication adherence after cognitive training.

The research design includes two parts: an eligibility screening and the Cognitive Training study. In Part 1, Eligibility Screening, participants will complete a 2-3 hour battery of standardized measures to assess for study eligibility. Eligible individuals will then be invited to enroll in Part 2, Cognitive Training Study. Part 1 of the study will involved screening approximately 60 participants, with an estimated eligibility rate of 67% for Part 2. In Part 2, participants will be assigned to one of two groups (active cognitive training or control training; 20 participants per group) and will complete 12 training sessions over 10 weeks. Participants assigned to the active cognitive training group will complete computerized modules designed to enhance working memory, while those assigned to the attention-matched control group will complete inactive modules that are not designed to enhance memory. All Part 2 participants will complete assessments at baseline and post-training to evaluate the impact of the training program.
The design of this cross-sectional study is centered around a structured questionnaire of a mixed qualitative and quantitative nature that is composed primarily of yes/no or Likert scale responses. All questions are written with the intent that they may be understood by those participants without any formal education. The investigators will recruit participants that are currently using the services of the Trifinio clinic in rural Guatemala as these are likely to fit inclusion criteria and will be able to benefit from potential future services that will be directed by the findings of this questionnaire. For all participants, Likert scale questions will be used with a series of faces to help indicate meanings for the answers and to decrease possibility of misinterpretation. Participants will be recruited through non-probabilistic sampling and the use of snowball sampling. Screening of these participants for exclusion criteria will be performed before questionnaires are distributed. The questions of the questionnaire are designed to elicit information about certain beliefs or preferences related to healthcare in a structured manner that allows us to compare answers and determine trends, prevalence, and associations that are likely to exist among community members. Participation will be completely voluntary and informed consent will be obtained from each participant before they are given the questionnaire. For participants who are illiterate or would prefer to have the informed consent and questionnaire read aloud to them, this will be done by one of the CITI-trained investigators. Recorded data will only include questionnaire responses and will not include any identifying information. We will be using randomized numbers in order to refer to completed questionnaires, but these numbers will have no identifying aspects and will be used for the sole purpose of keeping track of the gathered data. The information gathered will be de-identified and stored and password-protected through REDCap.
Introduction: Mindfulness interventions can improve a broad range of patient outcomes, but traditional mindfulness-based interventions are time and resource intensive. Emerging evidence indicates brief, single-session mindfulness interventions can also improve patient outcomes, and brief mindfulness interventions can be embedded into medical care pathways with minimal disruption. However, the direct impact of a brief mindfulness intervention on patients' pain while waiting in the clinic waiting room remains unexamined. Objective: A series of three, pilot, randomized controlled trials (RCTs) were conducted to examine the impact of a brief, audio-recorded, mindfulness intervention on patients' pain in the clinic waiting room. Method: Study 1 examined an 8-min mindfulness recording delivered before a provider visit; Study 2 examined a 5-min mindfulness recording after a provider visit; and Study 3 examined a 4-min mindfulness recording before a provider visit. Time- and attention-matched control conditions were used in each study. Studies 1 and 2 were conducted in an academic cancer hospital. Study 3 was conducted at a walk-in orthopedic clinic. Pain intensity was measured in each of the three studies. Anxiety and depression symptoms were measured in Studies 2 and 3. Pain unpleasantness was measured in Study 3. Results: A brief (i.e., 4- to 8-min), audio-recorded mindfulness intervention decreased patients' pain intensity in the clinic waiting room, whether delivered before (Study 1 Cohen's d=1.01, Study 3 Cohen's d=0.39) or after (Study 2 Cohen's d=0.89) a provider visit. Mindfulness had a significant effect on anxiety symptoms in both studies in which it was measured. No effect on depression symptoms was observed. Conclusions: Results from these three pilot RCTs indicate brief, audio-recorded, mindfulness interventions may be capable of quickly decreasing clinical symptoms. As such, embedding brief, audio-recorded, mindfulness interventions in clinic waiting rooms may have the potential to improve patient outcomes. The continued investigation of this intervention approach is needed. Clinical Trial Registrations: NCT04477278 and NCT06099964.
Patients undergo supervised exercise sessions comprising of AE over 30 minutes and RE over 25 minutes 3 days per week for 24 weeks. Patients are encouraged to complete AE at home over 20 minutes 1 day per week. Patients receive a Polar heart rate monitor to monitor heart rate during the AE sessions.
PROBLEM TO BE SOLVED: To obtain the subject new compound comprising a specific UCS1025 compound, having excellent antimicrobial and antitumor action and useful as an antimicrobial agent and an antitumor agent and a tautomer (salt) which is chemically equivalent thereto. SOLUTION: This new UCS1025 compound is represented by the formula (R is H or OH) or a tautomer which is chemically equivalent thereto or pharmacologically permissible salt thereof. The compound has excellent antimictobial and antitumor action and is useful as an antimicrobial agent, an antitumor agent, etc. The compound is obtained by culturing a microorganism belonging to the genus Acremonium and having UCS1025 compound-producing ability [e.g. Acremonium sp. KPC7629-19 (FERM BP-5673)] or a microorganism belonging to the genus Humicola and having UCS1025 compound-producing ability [e.g. Humicola sp. KPC7781-6 (FERM BP-5674)] in a medium and collecting the product from the cultured product.
PURPOSE:A mucosal application agent in the oral cavity, obtained by incorporating an anti-inflammatory and analgesic drug selected from steroidal and nonsteroidal drugs in a water-soluble film, capable of readily pressing the affected part precisely without sense of incompatibility and lasting drug effect with the dissolution thereof. CONSTITUTION:A mucosal application agent in the oral cavity obtained by incorporating an anti-inflammatory and analgesic agent selected from steroidal drugs, e.g. triamcinolone acetonide or dexamethasone, and nonsteroidal drugs, e.g. indomethacin or diclofenac sodium, in a water-soluble film, e.g. polyvinylpyrrolidone (PVP), gelatin or polyvinyl alcohol (PVA). The thickness of the water-soluble film is 20-300mum. The anti-inflammatory and analgesic agent contained in the water-soluble film acts directly on the affected part as the film dissolves in the oral cavity. The agent is capable of producing anti-inflammatory and analgesic action precisely on the affected part synergistically with structural characteristics of readily pressing the affected part.
A composition for the cold permanent waving of hair comprises a substantially single phase aqueous solution of a keratin-reducing agent, a dissolved or liquefied normally gaseous propellant and a solvent for the propellant, pressurized in and adapted for discharge from a container as a foam which collapses to a liquid promptly after discharge, e.g. within 30 seconds after discharge. The composition preferably comprises as keratin-reducing agent a water soluble mercaptan containing up to 6 carbon atoms and in addition to the mercapto group a carboxyl, hydroxyl or amido functional group, in an amount equivalent to 1-10% by weight of the composition of this glycollic acid, as propellant monochlorodifluoromethane, dichlorodifluoromethane, trichloromonofluoromethane, dichlorotetrafluoroethane, difluoroethane, monochlorodifluoroethane or a mixture thereof, as solvent water or a mixture thereof with one or more alcohols containing up to 6 carbon atoms per molecule and an alkalizing agent which is a weak base having buffering capacity and a dissociation constant of less than 10-3, e.g. ammonia, monoethanolamine, diethanolamine, tris-(hydroxymethyl)-amino methane, 2-amino-2-methyl-1, 3-propane diol, triethanolamine and glycerylamine, or a mixture of a major proportion of the weak base and a minor proportion of a strong base, e.g. sodium, lithium and potassium hydroxides and tetramethyl ammonium hydroxide, to impart to the composition a pH above 7 but below 10.  The composition may also contain ammonium carbonate or bicarbonate, anionic or nonionic surface active agents numerous examples of which are given, sequestering agents, e.g. the sodium, potassium, p  ammonium and alkanol ammonium salts of ethylene diamine tetraacetic acid, soluble salts of the disulphide of thioglycollic acid and perfumes.  The compositions may be packaged in pressure tight metal cans or glass bottles coated on the outside with plastic and having a valve-controlled opening to a foam nozzle which may be fitted with a comb type applicator. The hair may be treated with the composition before or after winding into curls and may subsequently be rinsed and dried and, if desired, treated with a fixing solution, e.g. sodium perborate. Specification 748,411 is referred to.